VEGF-D expression in brain cancer
OwnerWaldemar Debinski, Denise M. Giboinventors
Life of this patent
Estimating the term…
Abstract
VEGF-D serves as a target for diagnosing and treating glioblastoma multiforme and related brain cancers. Cancer in a brain tissue sample is detected by analyzing expression of VEGF-D in the sample. Brain cancer is treated by modulating VEGF-D gene expression in cells of the cancer, and by inhibiting angiogenesis associated with the cancer by interfering with VEGF-D binding to a VEGF-D receptor.
Claims43
A method for detecting a cancer in a brain tissue sample, the method comprising the steps of:
- (A) providing the brain tissue sample;
- and
- (B) analyzing the brain tissue sample for a VEGF-D marker.
A method of modulating VEGF-D gene expression in a brain cancer cell comprising the steps of:
- (A) providing a brain cancer cell that expresses a VEGF-D gene;
- and
- (B) introducing into the cell an agent that modulates the expression of the VEGF-D gene in the cell.
A method of identifying a test compound that modulates expression of a VEGF-D gene in a brain cancer cell, the method comprising the steps of:
- (A) providing a brain cancer cell expressing a VEGF-D gene;
- (B) contacting the cell with the test compound;
- and
- (C) detecting a modulation in the expression of the VEGF-D gene,
- wherein detecting the modulation indicates that the test compound modulates expression of the VEGF-D gene.
A method for inhibiting angiogenesis associated with a brain cancer in a subject, the method comprising the steps of:
- (A) providing a molecule that interferes with VEGF-D binding to a VEGF-D receptor;
- and
- (B) administering the molecule to the central nervous system of the subject in an amount effective to inhibit blood vessel development associated with the brain cancer.
Dependencies are inferred from the claim text.